UnitedHealth Stock Forecast: Trending Mixed Signals From Analysts

UnitedHealth Group (UNH) has staged a sharp rebound, with the stock up 11.7% over the past week and 29.8% over the past month, though it still sits 15.1% lower than a year ago. Wall Street’s analysts hold a ModerateBuy consensus on the shares, with a 12‑month average price target of $378.63 versus a recent close of $353.52, pointing to room for further gains.

Behind that consensus are two closely watched voices offering different levels of enthusiasm but a shared view that the business is strengthening. Kevin Fischbeck of BofA Securities reiterated a Hold rating on 4/22/2026 with a price target of $380, while Scott Fidel of Goldman Sachs reiterated a Buy with a more bullish $435 target. Both see earnings momentum improving after a stronger‑than‑expected first quarter.

Fischbeck describes the latest results as a beat‑and‑raise quarter that still looks conservative, highlighting Q1 2026 EPS of $7.23 that beat consensus by $0.70 and came with a guidance raise. He notes that the medical loss ratio of 83.9% beat expectations by 190 basis points thanks to better medical cost trends and favorable reserve development, but stays Neutral as he awaits more visibility on Medicare Advantage Stars and future MA rate notices.

The BofA analyst also points to rising operating costs, with an opex ratio of 13.8%, up 140 basis points year on year as UnitedHealth invests heavily in AI and consumer performance to drive earnings growth from 2027 onward. He sees UHC margins improving by 40 basis points even as Optum margins slipped, and flags strategic moves such as the planned acquisition of Alegeus Technologies, the sale of Optum UK, and a $2 billion share buyback as important long‑term levers.

Goldman Sachs’ Scott Fidel is more overtly bullish, arguing that UnitedHealth’s cyclical recovery is running “fast out of the starting gate” after Q1 2026 adjusted EPS beat Visible Alpha consensus by about 11%. Fidel believes significant underlying earnings power is being masked by elevated discretionary spending, including a sharp jump in incentive compensation, and sees all major business lines positioned to exceed current Street expectations for 2026.

Fidel highlights that management raised full‑year 2026 EPS guidance by $0.50 to at least $18.25, a move he views as stronger than investors anticipated this early in the year. He credits disciplined pricing, controlled medical cost trends, and favorable seasonal factors for the 83.9% medical loss ratio, and urges investors to continue accumulating the stock following the results. On TipRanks, Fischbeck ranks 3,424 out of 12,161 analysts with a 58.10% success rate and 2.8% average return, while Fidel ranks 1,280 with a 63.08% success rate and 8.8% average return. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.